Megoxi

Megestrol Acetate, the active ingredient in Megoxi, is a progestin presented as an oral tablet for oral use. It is employed as an appetite stimulant and hormone‑responsive cancer therapy, particularly in patients with AIDS‑related cachexia, cancer‑associated weight loss, or certain breast and endometrial cancers.

GNH USA supplies Megoxi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with established quality‑assured manufacturing and regulatory compliance across EU markets.

Megestrol acetate is a synthetic progestin used to address conditions associated with severe weight loss and hormone‑responsive tumors. - Cachexia associated with AIDS or cancer: improves appetite and promotes weight gain in patients experiencing disease‑related wasting. - Weight loss in chronic illness: helps increase body mass and nutritional status in patients with non‑cancer chronic conditions. - Hormone‑responsive cancers (breast, endometrial): used as part of therapy to inhibit tumor growth by anti‑estrogenic activity.

Megestrol acetate may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Weight gain: excessive increase beyond therapeutic goal. - Edema: peripheral swelling due to fluid retention. - Hot flashes: transient vasomotor symptoms. - Hyperglycemia: elevated blood glucose levels. - Cushingoid appearance: facial rounding and central obesity.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Adrenal suppression: reduced cortisol production requiring monitoring. - Severe hypersensitivity: rash, angioedema, or anaphylaxis. - Liver dysfunction: abnormal hepatic enzymes or hepatitis.

When prescribing megesterol acetate, several safety considerations should be observed. - Dose titration: adjust based on clinical response and weight changes. - Monitoring: regularly assess blood glucose, lipid profile, and signs of fluid retention. - Thrombotic risk: avoid in patients with history of clotting disorders. - Hormone‑sensitive tumors: evaluate benefits versus potential tumor progression. - Pregnancy and lactation: contraindicated unless benefits outweigh risks. - Store at ambient temperature: keep below 25 °C, protect from moisture and light in original container.

Megestrol acetate can interact with other medicines, requiring attention to potential effects.

Major Interactions (Avoid): - CYP3A4 inducers (e.g., rifampin): may reduce efficacy. - Anticoagulants (warfarin): increased risk of thrombosis. - Diabetic medications: may exacerbate hyperglycemia.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole): may increase plasma levels. - Other progestins or hormonal therapies: additive hormonal effects.